An antibody improved detection of TDP-43 pathology in ALS and related disorders
Original source
A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
Related topics
A phosphorylation-independent monoclonal antibody called MAb No. 9 detected TDP-43 pathology across amyotrophic lateral sclerosis (ALS) and several related neurodegenerative conditions in an autopsy study. It showed enhanced labeling of some fine and thread-like abnormalities compared with a commonly used phospho-specific antibody, although performance varied by pathology subtype and tissue damage. The findings support its potential use as a complementary research tool for studying TDP-43 disease.
Why this matters
The antibody may help researchers identify and compare TDP-43 abnormalities in donated brain tissue, refine disease subtypes, and develop biomarkers. This is an autopsy-based laboratory finding and does not change treatment or establish that the antibody can diagnose or monitor ALS in living people.
Limitations and context
The study examined postmortem tissue from a multicenter autopsy cohort rather than living patients. Its findings concern antibody labeling and associations with neurodegeneration, not clinical benefit or treatment response. Further work would be needed to determine whether the antibody improves biomarkers or diagnosis in living people.